Investee Company Update: Nuuvera

RNS Number : 0480C

FastForward Innovations Limited

16 January 2018

 

16^th January 2018

FastForward Innovations Limited

("FastForward")

Investee Company Update: Nuuvera and Globalive Technologies partners to bring blockchain to the global medical cannabis industry in groundbreaking collaboration

FastForward is pleased to note the announcement by investee company Nuuvera Corp. ("Nuuvera" (TSXV: NUU)), a public company formed to capitalize on the global trend towards the legalization of medical cannabis, in which FastForward has a holding of 3.75%. The full announcement is set out below. GTP is a Canadian company specializing in improving existing businesses and economies by utilizing disruptive technologies, specifically artificial intelligence, internet of things, and blockchain technology.

'Nuuvera Inc. ("Nuuvera") (TSXV: NUU) is proud to announce it is entering into a joint partnership with Globalive Technology Partners (GTP) to bring blockchain technology to the global cannabis market. 

Following the joint development of the blockchain technology, both Nuuvera and GTP will license the software around the globe to help increase the safety and security of records as well as help supply chain management globally. 

The first of its kind partnership will see Nuuvera and GTP developing proprietary blockchain technology that will help validate the integrity and grade of cannabis products, from source to consumer.

"We're extremely excited to partner with Anthony Lacavera and GTP on this disruptive global cannabis technology.  In applying blockchain technology to this emerging industry, we will continue to shape the global cannabis market, and set an incredibly high bar for safety and consistency that will benefit patients everywhere," said Nuuvera CEO, Lorne Abony. 

"Nuuvera's mission is to lead the emerging cannabis industry by developing safe, consistent, and effective products for patients. We are already leveraging the capabilities of our global network with an aim of becoming the most innovative cannabis company in the world. Through this partnership with GTP, we can use blockchain technology to ensure the integrity and grade of our products - from source to retail. This demonstrates our deep commitment to leading the global cannabis industry in a positive and meaningful way," Lorne continued.

GTP - who announced last week they will go public in 2018 -- is forming partnerships with a very select group of leading companies across a variety of sectors who recognize the strategic advantage of incorporating blockchain into their sectors. GTP have selected Nuuvera as the sole partner for the emerging and burgeoning global cannabis market.

Anthony Lacavera, co-founder and CEO of GTP stated, "At GTP we share Nuuvera's vision to help build an innovative and safe global cannabis market. We also want to see consumers receive the safest, highest quality products. That's why we are delighted to choose Nuuvera as our sole partner to bring machine intelligence and blockchain technology to the cannabis industry."

For more information on Nuuvera, please visit: www.nuuvera.com

Lorne Abony, CEO of Nuuvera, said

"We are hugely excited to be pioneering Blockchain technology into the medical Cannabis industry. With our multinational agreements we feel that Nuuvera is in prime position to revolutionise the medical cannabis sector.

"With offices in Toronto, Tel Aviv, Hamburg, and Milan, we are positioned to serve diversified international markets with medical grade cannabis products, and through Blockchain technology we feel we can further legitimise this fast growing global business" said Abony.'

For more information on Nuuvera, please visit: www.nuuvera.com 

About Nuuvera

Nuuvera is a global medical cannabis company founded on Canadian principles, and built with the whole world in mind. Nuuvera is currently working with partners in Germany, Israel and Italy, and is exploring opportunities in several other countries, to develop commercial production and global distribution of medical grade cannabis in legalized markets. Through its subsidiaries, ARA - Avanti Rx Analytics Inc. and Avalon Pharmaceutical Inc., Nuuvera holds a Dealer License (GMP) under the Narcotic Control Regulations and Office of Controlled Substances. Nuuvera is currently in the final stages of the Health Canada review process to become a Licensed Producer of medical marijuana under the ACMPR, and has recently received its "letter to build" approval.

For further information please visit www.fstfwd.co or contact:

FastForward  Innovations Limited [e-mail]   Sue Saunders/ Ian Burns

Beaumont Cornish Limited (Nomad) Tel: [phone] James Biddle / Roland Cornish

Optiva Securities Limited (Broker) Tel: [phone] Ed McDermott

CAUTIONARY STATEMENT

The AIM Market of London Stock Exchange plc does not accept responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives of FastForward Innovations Ltd. There can be no assurance that such statements will prove to be accurate, achievable or recognizable in the near term.

Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. FastForward Innovations assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014

 

END

 

 

UPDUNOVRWOAAAAR